ArticleOncogene2001
Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours.
Article in Oncogene, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 89 citations in OpenAlex.
- Identification of potential therapeutic targets in urothelial bladder carcinoma of Chinese population by targeted next-generation sequencing.Cancer biology & therapy · 2020Article
- Review
- Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers.Oncotarget · 2015Article
- Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006.Cancer · 2014Article
- Article
- Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers.Apoptosis : an international journal on programmed cell death · 2013Review
- Article
- Mutational activation of FGFR3: no involvement in the development of renal cell carcinoma.Journal of cancer research and clinical oncology · 2012Article
- A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges.Advances in urology · 2012Article
- Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.British journal of cancer · 2011Article
- Contemporary management of low-risk bladder cancer.Nature reviews. Urology · 2011Review
- Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).Expert reviews in molecular medicine · 2010Review
- Article
- Biology of urothelial tumorigenesis: insights from genetically engineered mice.Cancer metastasis reviews · 2009Review
- Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.Cancer metastasis reviews · 2009Review
- Article
- Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.Cancer research · 2008Article
- Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.World journal of urology · 2007Review
- Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis.British journal of cancer · 2006Article
- MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling.Molecular cancer research : MCR · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations in FGFR3 have been identified in several tumour types including bladder carcinoma, cervical carcinoma, and multiple myeloma. In bladder carcinoma, we recently identified FGFR3 mutations in 41% of tumours, making this the most frequently mutated putative oncogene identified in bladder cancer to date. We have now investigated the frequency of FGFR3 mutation in a panel of 125 tumours and 13 cell lines from various other organs. We analysed the mutation hotspots in exons 7, 10 and 15 by direct DNA sequencing, and found one mutation in exon 7 (S249C) in 1/28 (3.5%) cervical tumours. Mutations were not detected in stomach, rectum, colon, prostate, ovarian, breast, brain, or renal tumours, nor were they found in any of the cell lines included in this study. We conclude that FGFR3 is commonly mutated in bladder carcinoma and only rarely in cervical carcinoma. Several tumour types appear not to possess any mutations in FGFR3, suggesting that these mutations are important only in the development of certain types of tumour.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.